| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | CASSAVA SCIENCES INC - 8-K, Current Report | 2 | SEC Filings | ||
| Mi | Cassava Sciences, Inc.: Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ | 2 | GlobeNewswire (USA) | ||
| 15.04. | CASSAVA SCIENCES INC - 8-K, Current Report | 23 | SEC Filings | ||
| 15.04. | Cassava Sciences, Inc.: Redemption Date Announced for Warrants | 36 | GlobeNewswire (USA) | ||
| 25.03. | Cassava Sciences, Inc.: Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials | 373 | GlobeNewswire (Europe) | An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials... ► Artikel lesen | |
| 21.03. | (SAVA) - Analyzing Cassava Sciences' Short Interest | 13 | Benzinga.com | ||
| 12.03. | Cassava Sciences under scrutiny following a damaging FDA report | 34 | iNVEZZ.com | ||
| 12.03. | Cassava Sciences again under scrutiny over Alzheimer's drug research | 33 | Seeking Alpha | ||
| 04.03. | Cassava Sciences, Inc.: Cassava Sciences Announces Virtual Presentation at the AD/PD 2024 International Conference | 29 | GlobeNewswire (USA) | ||
| 28.02. | CASSAVA SCIENCES INC - 10-K, Annual Report | 5 | SEC Filings | ||
| 28.02. | Cassava Sciences Inc reports results for the quarter ended in December - Earnings Summary | 8 | Reuters | ||
| 28.02. | Cassava Sciences GAAP EPS of -$0.50 | 9 | Seeking Alpha | ||
| 28.02. | CASSAVA SCIENCES INC - 8-K, Current Report | 5 | SEC Filings | ||
| 28.02. | Cassava Sciences, Inc.: Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates | 268 | GlobeNewswire (Europe) | $121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over 555 Study Participants Have Completed Our... ► Artikel lesen | |
| 08.02. | Cassava Sciences (SAVA) Stock Pops on Positive Results in Simufilam Trial | 18 | InvestorPlace | ||
| 07.02. | Why Alzheimers-Drug Developer Cassava Sciences Stock Is Trending | 15 | Benzinga.com | ||
| 07.02. | CASSAVA SCIENCES INC - 8-K, Current Report | 4 | SEC Filings | ||
| 07.02. | Cassava Sciences, Inc.: No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months | 7 | GlobeNewswire (USA) | ||
| 03.02. | Is There Any Hope for Cassava Sciences Stock? | 14 | The Motley Fool | ||
| 29.01. | (SAVA) - Analyzing Cassava Sciences' Short Interest | 9 | Benzinga.com |
Seite:
1 2 3 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 4.650 |
| SUPER MICRO COMPUTER | 2.905 |
| BYD | 2.699 |
| BAYER | 2.685 |
| NEL | 2.070 |
| APPLE | 2.068 |
| NVIDIA | 1.881 |
| DEUTSCHE BANK | 1.826 |
| TUI | 1.788 |
| TESLA | 1.591 |
| MERCEDES-BENZ | 1.315 |
| AMAZON | 1.228 |
| VOLKSWAGEN | 1.198 |
| COMMERZBANK | 1.125 |
| NOVO NORDISK | 1.058 |
| PLUG POWER | 1.044 |
| AIXTRON SE | 1.016 |
| RHEINMETALL | 994 |
| DEUTSCHE LUFTHANSA | 955 |
| RWE | 954 |
| PFIZER | 904 |
| RENK GROUP | 870 |
| NORDEX | 859 |
| BASF | 837 |
| PAYPAL | 833 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
